Suppr超能文献

内脏动脉重建的结果:系统评价。

Outcomes of Visceral Arterial Reconstruction: A Systematic Review.

机构信息

158987Royal Free Hospital, London, UK.

8440West Hertfordshire Hospitals NHS Trust, Watford, UK.

出版信息

Vasc Endovascular Surg. 2022 Apr;56(3):290-297. doi: 10.1177/15385744211029112. Epub 2022 Feb 7.

Abstract

The study aimed to review the use of synthetic grafts (SGs) and autologous vein grafts (AVGs) in visceral arterial reconstruction (VAR) in chronic visceral ischaemia. Systematic review methodology was employed. Six studies were included (218 patients and 281 vessels). Two studies had data about AVG only, 3 had data about SG only and 1 had both AVG and SG data. Three studies reported outcomes for AVG (117 patients and 132 vessels revascularized). One-year primary patency was 87% (95% CI 71%, 97%). Graft thrombosis rate was 6% (95% CI 0%, 16%). Pooled stenosis rate at one-year was 11% (95% CI 1%, 28%). The 30-day (n = 96), one-year (n = 72) and 5-year mortality (n = 30) were 0%, 0% and 12%, respectively. Four studies reported outcomes for SGs (106 patients and 147 vessels). The pooled primary patency at one year was 100% (95% CI 99%, 100%). Pooled primary 5-year patency rate was 88% (95% CI 69%, 100%). There was no graft infection in 2 of the 3 studies. Overall pooled percentage of graft thrombosis and stenosis at one year was 0%. Jimenez et al. (2002) reported one graft thrombosis at 20 months and graft stenosis in 2 patients at 46 and 49 months. Illuminati et al (2017) reported graft thrombosis in 2/24 patients at 22 and 52 months. Thirty days, one-year and 5-year mortality was 1% (95% CI 0%, 6), 7% (95% CI 0%, 20%) and 39% (95% CI 11%), respectively. Patency was better with SG compared with AVG. Mortality was higher in the SG group. Graft dilatation does occur with vein grafts, but in this review no intervention was found necessary. Poorly designed studies, incomplete reporting and absence of morbidity and mortality indices preclude emphatic conclusions.

摘要

本研究旨在回顾合成移植物(SGs)和自体静脉移植物(AVGs)在慢性内脏缺血性内脏动脉重建(VAR)中的应用。采用系统评价方法。共纳入 6 项研究(218 例患者,281 支血管)。其中 2 项研究仅提供 AVG 数据,3 项研究仅提供 SG 数据,1 项研究同时提供 AVG 和 SG 数据。3 项研究报告了 AVG 的结果(117 例患者,132 支血管再通)。1 年通畅率为 87%(95%CI71%,97%)。移植物血栓形成率为 6%(95%CI0%,16%)。1 年时狭窄率为 11%(95%CI1%,28%)。30 天(n=96)、1 年(n=72)和 5 年死亡率(n=30)分别为 0%、0%和 12%。4 项研究报告了 SG 的结果(106 例患者,147 支血管)。1 年时的总通畅率为 100%(95%CI99%,100%)。1 年时的总通畅率为 88%(95%CI69%,100%)。3 项研究中有 2 项未发生移植物感染。1 年时总移植物血栓形成和狭窄率为 0%。Jimenez 等人(2002 年)报道了 1 例 20 个月时发生的移植物血栓形成和 2 例 46 个月和 49 个月时发生的移植物狭窄。Illuminati 等人(2017 年)报道了 24 例患者中有 2 例在 22 个月和 52 个月时发生移植物血栓形成。30 天、1 年和 5 年的死亡率分别为 1%(95%CI0%,6)、7%(95%CI0%,20%)和 39%(95%CI11%)。SG 的通畅率优于 AVG。SG 组的死亡率更高。静脉移植物确实会发生扩张,但在本研究中没有发现需要进行干预。设计不佳的研究、不完整的报告以及缺乏发病率和死亡率指标,使得我们无法得出明确的结论。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验